News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alvogen And Lotus Pharmaceuticals, Inc. Merge Asian Operations To Create Compelling Platform For International Growth


1/16/2014 9:29:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the multinational pharmaceuticals company, agreed in December 2013 to become the majority shareholder in Taiwanese Lotus Pharmaceuticals (“Lotus”) through a private placement of newly issued shares, acquiring up to 151 million shares in the company. The total transaction value will be approximately US$200 million (approx. NTD 6 billion). As a results of the transaction, Alvogen´s shareholding will be approximately 67% in Lotus.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES